These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
633 related articles for article (PubMed ID: 28628843)
1. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Stahl M; Walz MK; Riera-Knorrenschild J; Stuschke M; Sandermann A; Bitzer M; Wilke H; Budach W Eur J Cancer; 2017 Aug; 81():183-190. PubMed ID: 28628843 [TBL] [Abstract][Full Text] [Related]
2. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction. Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438 [TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial]. Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918 [No Abstract] [Full Text] [Related]
4. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683 [TBL] [Abstract][Full Text] [Related]
6. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936 [TBL] [Abstract][Full Text] [Related]
7. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Stahl M; Walz MK; Stuschke M; Lehmann N; Meyer HJ; Riera-Knorrenschild J; Langer P; Engenhart-Cabillic R; Bitzer M; Königsrainer A; Budach W; Wilke H J Clin Oncol; 2009 Feb; 27(6):851-6. PubMed ID: 19139439 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
9. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424 [TBL] [Abstract][Full Text] [Related]
10. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530 [TBL] [Abstract][Full Text] [Related]
11. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054 [TBL] [Abstract][Full Text] [Related]
12. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction]. Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322 [TBL] [Abstract][Full Text] [Related]
13. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115 [TBL] [Abstract][Full Text] [Related]
14. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826 [TBL] [Abstract][Full Text] [Related]
16. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728 [TBL] [Abstract][Full Text] [Related]
17. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C; Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394 [TBL] [Abstract][Full Text] [Related]
18. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M; Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363 [TBL] [Abstract][Full Text] [Related]
20. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]